Intake & Induction

For the patient’s admittance to the MAT program and initiation of medications to treat opioid use disorder.

Drug Safety Communications - FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain

This is an FDA warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. Despite these risks, buprenorphine is an important treatment option for opioid use disorder (OUD) and pain, and the benefits of these medicines clearly outweigh the risks.

Treating Concurrent Substance Use Among Adults

This guide provides considerations and strategies for clinicians and organizations implementing evidence-based practices. Approaches presented will assist clinicians, behavioral health organizations, primary care providers, insurers, and policy makers in understanding, selecting, and implementing evidence-based interventions that support adults with concurrent substance use and/or concurrent substance use disorders, including alcohol.